CRMD News and Press, CorMedix Inc. From 03/30/23

BERKELEY HEIGHTS, N.J., March 30, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced financial results for t...

BERKELEY HEIGHTS, N.J., March 21, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced that it will report...

BERKELEY HEIGHTS, N.J., Jan. 17, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced the following promotions...

Summary Assertio Holdings is a pharmaceutical company based on a niche model that is focused on digital, non-personal promotion. Last Q3 showed great revenue and cash flow growth. The company's growth strategy is based on market acquisitions. The share price valuation seems to b...

BERKELEY HEIGHTS, N.J., Dec. 06, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced the abstract publication...

Penny Stocks To Buy According To 5 Wall Street Analysts Contrary to popular opinion, penny stocks aren’t just lottery tickets or no-name companies. This year, more than others, this has become a fact, especially considering the massive sell-off in the broader markets. Househo...

Image source: The Motley Fool. CorMedix Inc Common Stock (NASDAQ: CRMD) Q3 2022 Earnings Call Nov 10, 2022 , 8:30 a.m. ET Operator Continue reading For further details see: CorMedix Inc Common Stock (CRMD) Q3 2022 Earnings Call Transcript...

CorMedix Inc. (CRMD) Q3 2022 Earnings Conference Call November 10, 2022 8:30 am ET Company Participants Joe Todisco - Chief Executive Officer Matt David - Executive Vice President, Chief Financial Officer Phoebe Mounts - Executive Vice President, General Counsel ...

CorMedix press release ( NASDAQ: CRMD ): Q3 GAAP EPS of -$0.17 beats by $0.06 . Revenue of $6.82M (-82.1% Y/Y). Total cash on hand and short-term investments as of September 30, 2022 was $59.0 million, excluding restricted cash of $0.2 million. The Company believes...

BERKELEY HEIGHTS, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced financial results ...